KR20230005937A - 바이러스 감염의 치료 또는 예방을 위한 클로파지민 조성물 및 방법 - Google Patents

바이러스 감염의 치료 또는 예방을 위한 클로파지민 조성물 및 방법 Download PDF

Info

Publication number
KR20230005937A
KR20230005937A KR1020227041996A KR20227041996A KR20230005937A KR 20230005937 A KR20230005937 A KR 20230005937A KR 1020227041996 A KR1020227041996 A KR 1020227041996A KR 20227041996 A KR20227041996 A KR 20227041996A KR 20230005937 A KR20230005937 A KR 20230005937A
Authority
KR
South Korea
Prior art keywords
clofazimine
pharmaceutically acceptable
inhalable
polymorph
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227041996A
Other languages
English (en)
Korean (ko)
Inventor
토마스 호프만
스테판 우퍼
존 제이 주니어 프리먼
Original Assignee
맨카인드 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 맨카인드 코포레이션 filed Critical 맨카인드 코포레이션
Publication of KR20230005937A publication Critical patent/KR20230005937A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020227041996A 2020-05-01 2021-04-30 바이러스 감염의 치료 또는 예방을 위한 클로파지민 조성물 및 방법 Pending KR20230005937A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063018677P 2020-05-01 2020-05-01
US63/018,677 2020-05-01
PCT/US2021/030155 WO2021222740A1 (en) 2020-05-01 2021-04-30 Clofazimine composition and method for the treatment or prophylaxis of viral infections

Publications (1)

Publication Number Publication Date
KR20230005937A true KR20230005937A (ko) 2023-01-10

Family

ID=78332269

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227041996A Pending KR20230005937A (ko) 2020-05-01 2021-04-30 바이러스 감염의 치료 또는 예방을 위한 클로파지민 조성물 및 방법

Country Status (9)

Country Link
US (1) US20230248722A1 (https=)
EP (1) EP4142691A4 (https=)
JP (1) JP2023524064A (https=)
KR (1) KR20230005937A (https=)
CN (1) CN115666510A (https=)
AU (1) AU2021263580A1 (https=)
BR (1) BR112022022081A2 (https=)
CA (1) CA3177438A1 (https=)
WO (1) WO2021222740A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240390366A1 (en) * 2021-11-30 2024-11-28 Mannkind Corporation Formulation and method for topical treatment of mycobacterium ulcerans in buruli ulcers
WO2025091042A1 (en) * 2023-10-27 2025-05-01 Mannkind Corporation Methods for treating non-tuberculous mycobacterial infection

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071127B2 (en) * 2006-10-24 2011-12-06 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
ES2929343T3 (es) 2008-06-13 2022-11-28 Mannkind Corp Inhalador de polvo seco accionado por aspiración para la administración de fármacos
EP2496253B1 (en) * 2009-11-02 2019-01-09 MannKind Corporation Apparatus and method for cryogranulating a pharmaceutical composition
AU2014228415B2 (en) * 2013-03-15 2018-08-09 Mannkind Corporation Microcrystalline diketopiperazine compositions and methods
CA2943049A1 (en) * 2014-04-08 2015-10-15 Aradigm Corporation Liposomal ciprofloxacin formulations with activity against non-tuberculous mycobacteria
CA2965258C (en) * 2014-10-24 2023-09-19 Redhill Biopharma Ltd. Therapy for inhibition of single-stranded rna virus replication
US20160220710A1 (en) * 2015-01-30 2016-08-04 The Regents Of The University Of Michigan Compositions and methods for delivering pharmaceutical agents
CN108853106B (zh) * 2017-05-09 2021-02-02 中国食品药品检定研究院 亚胺吩嗪类化合物作为狂犬病病毒抑制剂的用途
US20200297626A1 (en) * 2017-10-02 2020-09-24 Board Of Regents, The University Of Texas System Inhalable composition of clofazimine and methods of use thereof
WO2019110099A1 (en) * 2017-12-06 2019-06-13 Qrumpharma Inc. Inhalable clofazimine formulation
KR102834026B1 (ko) * 2018-08-23 2025-07-14 맨카인드 코포레이션 클로파지민의 조성물, 이들을 포함하는 조합물, 이들의 제조 방법, 이들을 포함하는 용도 및 방법

Also Published As

Publication number Publication date
JP2023524064A (ja) 2023-06-08
EP4142691A4 (en) 2024-05-15
US20230248722A1 (en) 2023-08-10
AU2021263580A1 (en) 2022-11-24
EP4142691A1 (en) 2023-03-08
CN115666510A (zh) 2023-01-31
CA3177438A1 (en) 2021-11-04
WO2021222740A1 (en) 2021-11-04
BR112022022081A2 (pt) 2022-12-13

Similar Documents

Publication Publication Date Title
US8858917B2 (en) Methods for limiting spread of pulmonary infections
AU2021261049A1 (en) Products of manufacture and methods for treating, ameliorating or preventing microbial infections
AR049010A1 (es) Formulaciones farmaceuticas para inhaladores de polvos secos que comprenden un ingrediente activo presente en concentraciones reducidas
KR20230005937A (ko) 바이러스 감염의 치료 또는 예방을 위한 클로파지민 조성물 및 방법
WO2015027848A1 (zh) 含有帕拉米韦和/或其衍生物制剂的给药方法
AU701590B2 (en) Compounds and compositions for administration via oral inhalation or insufflation
WO2012051050A1 (en) Method for treating cystic fibrosis with inhaled denufosol
Thai et al. Development of inhalable formulations of anti-inflammatory drugs to potentially treat smoke inhalation injury in burn victims
US20050220720A1 (en) Formulations limiting spread of pulmonary infections
Balducci et al. Drug delivery strategies for pulmonary administration of antibiotics
HK40083799A (en) Clofazimine composition and method for the treatment or prophylaxis of viral infections
CA3219943A1 (en) Dry powder formulations of tacrolimus for administration by inhalation once daily (qd)
CN116916889A (zh) 用于肺高压领域的吸入式伊马替尼
WO2010009288A1 (en) Compositions and uses of antiviral active pharmaceutical agents
JP6908523B2 (ja) ネブライザー用組成物
EP4304552A1 (en) Novel antiviral compositions and their use in therapy and in the treatment of viral infections
HK40091740A (zh) 用於治疗、改善或预防微生物感染的制造产品和方法
HK40118869A (zh) 吸入用粉末及其生产方法
WO2015027847A2 (zh) 含有奥司他韦羧酸胍基类似体和/或其乙酯制剂的给药方法
JP2024170686A (ja) 新規医薬
Abdalaziz et al. Formulation strategy for hydroxychloroquine as inhaler dosage from as a potential for COVID-19 treatment

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000